E-cadherin monoclonal antibodies (mAbs) enhance epithelial barrier function and limit IBD progression.E-cadherin activating mAbs reduce loss of barrier function and inflammatory progression in IBD. The gene discussed is CDH1; the disease is inflammatory bowel disease.